Date: 2014-04-24
Type of information: Collaboration agreement
Compound: Soluprick® SQ Alutard SQ®
Company: ALK Abello (Denmark) Eddingpharm (China)
Therapeutic area: Allergic diseases - Immunological diseases
Type agreement: collaboration
Action mechanism:
Disease: house dust mite allergy
Details: * On April 24, 2014, ALK and China-based specialty pharmaceutical company Eddingpharm, have announced that they have agreed a collaboration that will expand ALK\'s presence in China. Under the agreement, Eddingpharm will handle the sales and distribution of ALK\'s marketed products in China, while ALK will support Eddingpharm with medical and scientific expertise. ALK will maintain a local organisation in China. The agreement covers ALK\'s diagnostic skin prick test, Soluprick® SQ, for house dust mite allergy, and the subcutaneous immunotherapy (SCIT) product, Alutard SQ®, also for house dust mite allergy. The collaboration will run for an initial seven years, provided certain performance targets are met. Under the terms of the new agreement, Eddingpharm will make an upfront payment to ALK to secure exclusive rights in China to Alutard SQ® and Soluprick®.
Financial terms:
Latest news:
